Connor, Clark & Lunn Investment Management (CC&L)
MRNS

Connor, Clark & Lunn Investment Management (CC&L)’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,335
Closed -$253K – 1591
2023
Q2 		$253K Buy
+23,335
New +$200K ﹤0.01% 1147

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s MRNS Position: Q3 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2023, closing a stake of 23,335 shares — an estimated $253K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in MRNS in Q2 2023 and held it in 1 quarter. The position peaked at $253K in Q2 2023. 104 funds tracked by Wall St. Rank hold MRNS as of Q3 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 23,335 Marinus Pharmaceuticals, Inc shares in Q3 2023, an estimated $253K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Marinus Pharmaceuticals, Inc in Q2 2023 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Marinus Pharmaceuticals, Inc position peaked at $253K in Q2 2023.
  • 104 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2023, filed 13 Nov 2023.